Amicus Filers Support Drugmakers’ Petition For Review Of Class Certification Case

( January 7, 2026, 2:18 PM EST) -- WASHINGTON, D.C. — A pair of organizations representing business and biopharmaceutical research interests urged the U.S. Supreme Court to grant a petition for a writ of certiorari filed by two drug makers to resolve “an important, recurring question concerning courts’ authority to deviate from” the requirements under Federal Rule of Civil Procedure 23(b)(3) in a putative class action....

Attached Documents

Related Sections